Stefano Mancon
Overview
Explore the profile of Stefano Mancon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kardoust Parizi M, Singla N, Matsukawa A, Tsuboi I, Mancon S, Miszczyk M, et al.
BJU Int
. 2025 Mar;
PMID: 40070078
Objectives: To evaluate the results of randomised controlled trials (RCTs) regarding the efficacy of human papillomavirus (HPV) vaccination in preventing male genital-related diseases. Methods: A systematic search of English language...
2.
Tsuboi I, Matsukawa A, Kardoust Parizi M, Schulz R, Mancon S, Fazekas T, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102306.
PMID: 39952876
Despite currently used intravesical therapies in non-muscle-invasive bladder cancer (NMIBC), the rate of intravesical recurrence remains very high. We aimed to evaluate the effectiveness of adding nonintravesical interventions to standard...
3.
Bernardini B, Piccioni F, Pastore M, Casale P, Buffi N, Lughezzani G, et al.
BJUI Compass
. 2025 Jan;
6(1):e376.
PMID: 39877577
Background: Despite guideline recommendations, few institutions have implemented clinical pathways that incorporate frailty into routine decision-making for patients undergoing radical cystectomy (RC). This paper presents an integrated clinical pathway designed...
4.
Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857987
: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the...
5.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2025 Jan;
PMID: 39848859
Background And Objective: There is an established association between secondary bladder cancers (SBCs) and radiotherapy (RT) for prostate cancer (PC), which remains a significant concern. Our aim was to update...
6.
Sordelli F, Desai A, Dagnino F, Contieri R, Giuriolo S, Paciotti M, et al.
Eur Urol Open Sci
. 2025 Jan;
71():172-179.
PMID: 39845740
Background And Objective: Bladder cancer (BC) represents a significant health care challenge and is frequently detected during evaluations for haematuria in emergency departments (EDs). Our aim was to evaluate the...
7.
Cadenar A, Mancon S, Shariat S, DAndrea D
Curr Opin Urol
. 2025 Jan;
35(2):189-193.
PMID: 39820224
Purpose Of Review: This review explores the potential role of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) for oligometastatic bladder cancer (OMBC) treatment. We focused on extrapolating evidence from...
8.
Bighetti S, Mancon S, Suardi N, Calzavara-Pinton P, Maione V, Arisi M, et al.
Australas J Dermatol
. 2025 Jan;
66(2):e39-e42.
PMID: 39812233
Objectives: This study aimed to evaluate the prevalence of lichen sclerosus (LS) in male patients undergoing circumcision for phimosis, emphasising the significance of a multidisciplinary approach in the early diagnosis...
9.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39578213
Background And Objective: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). It is highly invasive and associated with perioperative risks, while bladder-preserving trimodality therapy (TMT) offers...
10.
Matsukawa A, Yanagisawa T, Rajwa P, Fazekas T, Miszczyk M, Tsuboi I, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102251.
PMID: 39571519
Background: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed...